Haixi Pharma Completes Phase I of Oral HX9428 in nAMD with Visual Gains, Files IND for DME Phase IIa as FDA Fast Track Asset Expands
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced dual clinical progress updates for HX9428, its...
HKG: 2637
Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...
Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases
Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...